- |||||||||| chlorogenic acid / Jiuzhang Biotech
Journal: Chlorogenic acid improves growth performance and intestinal health through autophagy-mediated nuclear factor erythroid 2-related factor 2 pathway in oxidatively stressed broilers induced by dexamethasone. (Pubmed Central) - Aug 31, 2022
Interactions occurred between DEX and CGA for the ADG, F:G ratio, villus height, crypt depth, V/C value, and SOD, CAT, GST, and HO-1 activities, MDA and PCO levels, LC3-II/LC3-I value, and expressions of LC3-I, LC3-II, Beclin1, ATG7, Caspase-3, Caspase-9, Occludin, ZO-1, Keap1, Nrf2, HO-1, NQO-1, and p62. In conclusion, CGA improved the growth performance and intestinal health of oxidatively stressed broilers by activating the autophagy-mediated Nrf2 pathway.
- |||||||||| dexamethasone / Generic mfg., cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
Journal: Multiple myeloma in Latin America. (Pubmed Central) - Aug 31, 2022
Efforts must be made at the national health system level in our countries to offer our vast majority of MM patients a real chance to improve results in the diagnostic, risk stratification, and treatment. Currently, several groups in our region are working to make an impact in the field of MM.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Efleira (netakimab) / Biocad
Observational data, Journal: Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study. (Pubmed Central) - Aug 31, 2022
The significant increase in blood neutrophil count in the netakimab group may reflect efflux of neutrophils from inflamed tissues. We therefore hypothesize that neutrophil count and neutrophil-to-lymphocyte ratio could serve as markers of therapeutic efficiency for IL-17A-blocking antibodies in the context of active inflammation.
- |||||||||| svH1C / Susavion, svL4 / Susavion
Journal: Resolution of Eczema with Multivalent Peptides. (Pubmed Central) - Aug 31, 2022
In contrast, topical application of 1 μM svH1C, a peptide mimetic of sialic acid that lacks glutamine residues, or 1 μM dexamethasone was ineffective in restoring normal epidermal morphology. The data suggest that svL4 would be a powerful treatment for resolving severe eczema.
- |||||||||| triamcinolone acetonide / Generic mfg., 5-fluorouracil / Generic mfg.
Journal: A new treatment modality for the enlarged extraocular muscles. (Pubmed Central) - Aug 31, 2022
The data suggest that svL4 would be a powerful treatment for resolving severe eczema. The new protocol of the treatment is a promising modality that can be used in the chronic non-infectious inflammation without extensive fibrosis.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Mycoplasma Hominis: A Rare Case of Acute Otitis Media and Facial Nerve Paralysis. (Pubmed Central) - Aug 31, 2022
A 24-year-old male with multiple sclerosis, on rituximab, presented to the emergency department with otalgia and facial paralysis...The patient was admitted and started on IV ampicillin/sulbactam, IV dexamethasone, and ciprofloxacin/dexamethasone otic drops...Facial paralysis is an uncommon complication of AOM but typically resolves once appropriate antibiotic therapy is regimented. Because Mycoplasma can be missed on routine culture, clinicians should consider workup for atypical organisms in settings of immunosuppression so appropriate antibiotic therapy can be initiated.
- |||||||||| dexamethasone / Generic mfg.
Trial initiation date: Preoperative Corticosteroids in Autoimmune Thyroid Disease (clinicaltrials.gov) - Aug 31, 2022
P4, N=76, Not yet recruiting,
Because Mycoplasma can be missed on routine culture, clinicians should consider workup for atypical organisms in settings of immunosuppression so appropriate antibiotic therapy can be initiated. Initiation date: Jul 2022 --> Oct 2022
- |||||||||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion, Enrollment change, Surgery: Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery (clinicaltrials.gov) - Aug 31, 2022
P4, N=46, Completed,
Recruiting --> Active, not recruiting | N=120 --> 76 | Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022 Recruiting --> Completed | N=30 --> 46
- |||||||||| dexamethasone injection / Generic mfg.
Journal: Axial Length as a Risk Factor for Steroid-Induced Ocular Hypertension. (Pubmed Central) - Aug 30, 2022
Our findings indicate that a long AXL is a risk factor for steroid-induced OHT. Further, clinicians should be aware of steroid-induced OHT when treating patients with high myopia with steroids.
- |||||||||| dexamethasone / Generic mfg.
Journal: Recurrent suicide attempts affect normalization of HPA axis dysregulation after recovery from major depression. (Pubmed Central) - Aug 30, 2022
Using the combined dexamethasone suppression/corticotropin-releasing hormone (dex/CRH) test, we assessed HPA axis regulation in acute depression (N = 237) and after recovery with respect to previous suicide attempts...Our findings suggest that patients with a history of suicide attempts belong to a subgroup of individuals that exhibit a distinct pattern of stress hormone response during acute depression and after recovery. Future studies may extend our approach by investigating additional psychological stress tasks to gain a broader understanding of the stress pathology of recurrent suicide attempters.
- |||||||||| dexamethasone / Generic mfg., prednisolone / Generic mfg.
Journal: Combined Intratympanic and Systemic Steroid Therapy in Sudden Sensorineural Hearing Loss. (Pubmed Central) - Aug 30, 2022
The mean audiometric gain was 37.71 dB in recovered cases. The combination therapy of intratympanic dexamethasone and oral steroid is more effective in comparison with intratympanic or oral steroid alone in the treatment of SSNHL as the patients benefitted from the therapeutic effects of both local and systemic steroids.
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Journal: Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. (Pubmed Central) - Aug 30, 2022
A propensity score matching was performed by taking into account the following stratification factors: sex (male vs. female), age (< vs. ≥70 years old), overweight (body mass index, BMI < vs. ≥25), underweight (BMI < vs. ≥19), disease spread (early vs. advanced/metastatic), tumor type (esophagogastric cancer vs. the rest, hepatobiliary tumor vs. the rest, colorectal cancer vs. the rest), type of NK1-RA used as primary/secondary prophylaxis (netupitant-palonosetron vs. fosaprepitant/aprepitant), concomitant use of opioids (yes vs. no), concomitant use of antidepressant/antipsychotic drugs (yes vs. no), Eastern Cooperative Oncology Group (ECOG) performance status at the start of NK1-RA treatment (0 vs. 1-2), and intensity of chemotherapy regimen (doublet vs. triplet)...Finally, chemotherapy delays (p = 0.000009) and chemotherapy dose reductions (p = 0.0000006) were less frequently observed in primary NK1-RA users. In patients affected by gastrointestinal malignancies, a primary CINV prophylaxis with NK1-RA, 5HT3-RA, and dexamethasone might be appropriate, particularly in those situations at higher risk of emesis and in which it is important to avoid dose delays and/or dose reductions, keeping a proper dose intensity of chemotherapy drugs.
- |||||||||| dexamethasone / Generic mfg.
Observational data, Journal: Comparing the Characteristics of Mucormycosis Between Cases with and without COVID-19; a Cross-sectional Study. (Pubmed Central) - Aug 30, 2022
Univariate analysis showed the association of in-hospital mortality with need for ventilation (p < 0.001), sinus involvement (p = 0.040), recent use of dexamethasone (p = 0.011), confirmed COVID-19 disease (p = 0.025), mean body mass index (BMI) (p =0.035), hemoglobin A1c (HbA1c) (p = 0.022), and median of blood urea nitrogen (BUN) (p =0.034)...The mucormycosis cases with concomitant COVID-19 disease had higher frequency of cough and shortness of breath, higher frequency of acute presentation, higher need for immunosuppressive, corticosteroid, and ventilator support, and higher mortality rate. The two groups were the same regarding age, gender, BMI, risk factors, underlying diseases, symptoms, and sites of involvement.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Salvia officinalis leaf extracts protect against acute colitis in rats. (Pubmed Central) - Aug 30, 2022
Prepared extracts, dexamethasone (1 mg/kg, i.p.), and mesalamine (100 mg/kg) as reference drugs and normal saline as control were administered by gavage, 2 h before colitis induction and preserved for four further days to animals...It seems S. officinalis could exert protection against oxidative stress and inflammatory mediators in colitis tissue. More experimental and clinical studies are required to explore the exact mechanisms and active ingredients which are involved.
- |||||||||| dexamethasone / Generic mfg.
Journal: The role of PTEN in puromycin aminonucleoside-induced podocyte injury. (Pubmed Central) - Aug 30, 2022
In this study, We therefore investigated whether PTEN could play a role in podocyte injury induced by puromycin aminonucleoside (PAN), and whether dexamethasone (DEX) alleviates podocyte injury by PTEN/PI3K/Akt signaling. Our results showed that PI3K/Akt pathway was activated in podocytes exposed to PAN conditions, accompanied by down-regulation of the PTEN and microtubule-associated light chain 3 (LC3) expression.podocyte-specific knockout of PTEN significantly promoted podocyte injury, The potential renoprotection of overexpressed PTEN in podocytes was partly attributed with an improvement in autophagy and the inhibition of apoptosis.These novel findings also suggest that targeting PTEN might be a novel and promising therapeutic strategy against podocyte injury.
- |||||||||| dexamethasone / Generic mfg.
Journal: A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity. (Pubmed Central) - Aug 30, 2022
We discovered that culturing HuH-7 human hepatoma cells with dexamethasone (DEX) and 0.5% dimethyl sulfoxide (DMSO) for two weeks, with Matrigel overlay after one week, resulted in a shorter and improved differentiation process...Differentiated HuH-7 cells displayed a marked shift in bile acid composition and induction of cytochrome P450 (CYP) 7A1, CYP8B1, CYP3A4, and bile acid-CoA: amino acid N-acyltransferase (BAAT) mRNAs compared to control. Inhibition of taurocholate uptake and excretion after a 24-h treatment with prototypical cholestatic drugs suggests that differentiated HuH-7 cells are a suitable model to examine cholestatic hepatotoxicity.
- |||||||||| prednisolone / Generic mfg., acyclovir / Generic mfg.
Journal: Thrombotic Microangiopathy Secondary to Disseminated Varicella Zoster Virus Infection in an Adult Patient. (Pubmed Central) - Aug 30, 2022
Compared to the pediatric population, VZV infection tends to be more severe in the adult age group. This case demonstrates that a high index of suspicion for TMA in adult patients with VZV who present with thrombocytopenia, even when there is no definitive diagnosis, can result in early management with favorable outcome.
- |||||||||| prednisolone / Generic mfg.
Trial completion date, Trial primary completion date: RhinoPOCRCT: Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age (clinicaltrials.gov) - Aug 30, 2022
P4, N=210, Not yet recruiting,
For pancreatitis with unknown causes, related immunological parameters should be tested, and symptoms of the other systems should be closely monitored to avoid delaying the diagnosis. Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2024 --> Sep 2025
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial initiation date, Trial primary completion date: The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis (clinicaltrials.gov) - Aug 30, 2022
P2/3, N=60, Recruiting,
Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2024 --> Sep 2025 Trial completion date: May 2022 --> Jul 2025 | Initiation date: May 2022 --> Aug 2022 | Trial primary completion date: May 2022 --> Jan 2025
- |||||||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Enrollment closed, Metastases: Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 30, 2022
P2, N=60, Active, not recruiting,
Not yet recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2022 Recruiting --> Active, not recruiting
- |||||||||| dexamethasone / Generic mfg.
Journal: Approach to the patient: Diagnosis of Cushing's syndrome. (Pubmed Central) - Aug 30, 2022
First-line screening tests including the 1-mg dexamethasone suppression test, 24-hour urinary free cortisol excretion, and late-night salivary cortisol measurement should be performed to screen for endogenous Cushing's syndrome...In this issue of 'Approach to the patient' the diagnostic workup of Cushing's syndrome is discussed with answering the questions when to screen, how to screen and how to differentiate the different causes. In this respect, latest developments in biochemical and imaging techniques are discussed as well.
|
